Stock listing

NKTR Stock Price, News, Filings & Events — Nektar Therapeutics

Selected listing: NKTR · BX · CHF · CH

This page tracks Nektar Therapeutics's NKTR:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following NKTR:BX. NKTR:BX is the stock-level entry point for investors researching Nektar Therapeutics, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Nektar Therapeutics is a public company traded under the ticker NKTR in the American market, with a market capitalization of approximately $2.39 billion. The company focuses on developing innovative therapies to address unmet medical needs. Nektar is dedicated to advancing its pipeline of drug candidates and improving patient outcomes.

NKTR:BXCHFCHUpdated August 21, 2026
Nektar Therapeutics logo
Ticker
NKTR:BX
Asset type
Stock
Market cap
$2.53B
Sector
Health Technology
Industry
Pharmaceuticals: Major
Exchange
BX
Currency
CHF

Nektar Therapeutics NKTR:BX stock context

This page tracks Nektar Therapeutics's NKTR:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following NKTR:BX. NKTR:BX is the stock-level entry point for investors researching Nektar Therapeutics, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Nektar Therapeutics is a public company traded under the ticker NKTR in the American market, with a market capitalization of approximately $2.39 billion. The company focuses on developing innovative therapies to address unmet medical needs. Nektar is dedicated to advancing its pipeline of drug candidates and improving patient outcomes.

Latest news from Nektar Therapeutics

All Nektar Therapeutics news →

Research Nektar Therapeutics

Alternate listings